Scholar Rock - SRRK Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings or view top-rated stocks.

6 brokers have issued 12-month target prices for Scholar Rock's shares. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they expect the company's share price to reach $26.00 in the next year. This suggests a possible upside of 227.9% from the stock's current price.
View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts.

Scholar Rock's stock was trading at $24.84 at the start of the year. Since then, SRRK shares have decreased by 68.1% and is now trading at $7.93.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our SRRK earnings forecast.

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Monday, November, 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.17. The firm had revenue of $5.46 million for the quarter, compared to the consensus estimate of $4.65 million. Scholar Rock had a negative trailing twelve-month return on equity of 54.30% and a negative net margin of 236.95%. The business's revenue for the quarter was up 79.9% compared to the same quarter last year. During the same period last year, the business earned ($0.79) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (19.57%), Vanguard Group Inc. (5.34%), BlackRock Inc. (3.72%), Laurion Capital Management LP (1.57%), State Street Corp (0.88%) and Citadel Advisors LLC (0.86%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus.
View institutional ownership trends.

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRRK stock can currently be purchased for approximately $7.93.

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $409.66 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis.

The company employs 145 workers across the globe.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.